Literature DB >> 30195334

Inflammatory myofibroblastic tumor of the pleura with adjacent chest wall invasion and metastasis to the kidney: a case report.

Yong-Sub Na1, Sang-Gon Park2.   

Abstract

BACKGROUND: Inflammatory myofibroblastic tumor is a rare benign neoplasm that frequently involves the lung and abdominopelvic region, and is found mainly in children and young adults. Inflammatory myofibroblastic tumor tends to be locally invasive or recurrent, and rarely metastasizes. CASE
PRESENTATION: A 76-year-old Korean man presented with a history of upper back pain for 2 months and motor weakness in both lower extremities for 2 days. Contrast-enhanced computed tomography of his chest and abdomen showed a large heterogeneous pleural mass involving the right fifth rib and vertebral body and a mass infiltrating the right renal hilum. Computed tomography-guided percutaneous needle biopsy of the pleural mass was performed. The histological findings on hematoxylin and eosin staining showed proliferation of spindle cells with infiltration of lymphocytes and plasma cells. Immunohistochemistry showed neoplastic cells positive for CD68, focally positive for smooth muscle actin, and negative for cytokeratin and desmin. Inflammatory myofibroblastic tumor was diagnosed based on the histological examination. Treatment with glucocorticoids (methylprednisolone 1 mg/kg) and radiotherapy (5 days/week for 3 weeks at 3 Gy/fraction, 45 Gy/15 days) was started. After 1 month, chest computed tomography showed a reduction in the size of the pleural mass, and abdominopelvic computed tomography showed decreased infiltration around the right renal pelvis.
CONCLUSIONS: Inflammatory myofibroblastic tumor is a rare neoplasm of intermediate malignant potential due to a tendency for local recurrence and it rarely develops distant metastases. Complete surgical resection is the primary treatment. However, unresectable and metastatic inflammatory myofibroblastic tumor can be treated with systemic therapy, including glucocorticoids, radiotherapy, and/or chemotherapy.

Entities:  

Keywords:  Inflammatory myofibroblastic tumor; Kidney; Metastasis; Pleura; Treatment

Mesh:

Year:  2018        PMID: 30195334      PMCID: PMC6129296          DOI: 10.1186/s13256-018-1796-7

Source DB:  PubMed          Journal:  J Med Case Rep        ISSN: 1752-1947


Background

Inflammatory myofibroblastic tumor (IMT) is a rare benign neoplasm that frequently involves the lung and abdominopelvic region, and is mainly found in children and young adults [1]. The histological features of IMT include proliferation of spindle cells with a prominent inflammatory infiltrate consisting of plasma cells and lymphocytes, with occasional eosinophils and neutrophils [2]. IMT tends to be locally invasive or recurrent, and rarely metastasizes [3]. Pulmonary IMT most commonly presents as a solitary pulmonary nodule or well-circumscribed mass on chest radiography [4, 5], but rarely presents in the pleura [6]. Here we present the case of a 76-year-old Korean man with pleural IMT involving the adjacent chest wall, with metastasis to the kidney.

Case presentation

A 76-year-old Korean man presented with upper back pain for 2 months and motor weakness in both lower extremities for 2 days. A chest radiograph and computed tomography (CT) performed at another institution showed a pleural mass in the upper lobe of his right lung. He was referred to our hospital for evaluation of the pleural mass and paraplegia. He had been treated with medication for 4 years for type 2 diabetes mellitus and primary hypertension. He did not have a family history of malignant disease. On chest examination, he had tenderness at the level of the fifth rib on the right side. On neurologic examination, he showed paraplegia with numbness and a sensory deficit below the T5 dermatome. Laboratory findings showed an elevated C-reactive protein level of 6.84 mg/dL (normal range, 0.0–0.3 mg/dL), blood urea nitrogen of 25 mg/dL (normal range, 7.8–22.0 mg/dL), and a serum creatinine of 1.5 mg/dL (normal range, 0.6–1.4 mg/dL). Urine analysis showed 4+ blood, with many red blood cells and 0–1 white blood cells/high-power field (Table 1).
Table 1

Laboratory data at admission and follow-up

VariableAdmissionHD #18HD #28
WBCs (× 103/μL)10.177.224.99
Hb (g/dL)14.111.812.3
Platelets (×103/μL)243219126
ESR (mm/hour)291314
CRP (mg/dL)6.840.550.64
BUN (mg/dL)2522.515.0
Creatinine (mg/dL)1.50.810.82
Urinalysis
 Blood4+NegativeNegative
 Protein+/−NegativeNegative
Urine microscopy
 Red blood cellsMany/hpf1–4/hpf1–4/hpf
 White blood cells0–1/hpf10–19/hpf5–9/hpf
Clinical courseHydration BiopsySteroid therapy RadiotherapySteroid therapy

BUN blood urea nitrogen, CRP C-reactive protein, ESR erythrocyte sedimentation rate, Hb hemoglobin, HD hospital day, hpf high-power field, WBC white blood cell

Laboratory data at admission and follow-up BUN blood urea nitrogen, CRP C-reactive protein, ESR erythrocyte sedimentation rate, Hb hemoglobin, HD hospital day, hpf high-power field, WBC white blood cell A chest radiograph showed a large homogenous opacity in the right superior mediastinum. Contrast-enhanced chest CT showed a 7.3 cm × 4.4 cm × 7.7 cm heterogeneous pleural mass involving the right fifth rib and vertebral body (Fig. 1a).
Fig. 1

Contrast-enhanced computed tomography and magnetic resonance imaging study at admission. a Contrast-enhanced chest computed tomography shows a large heterogeneous pleural mass involving the right fifth rib and vertebral body. b Contrast-enhanced abdominopelvic computed tomography shows a mass infiltrating the right renal hilum (longest diameter, 44 mm). c Axial T1-weighted magnetic resonance imaging shows a pleural mass with high signal intensity extending to rib, muscle, and vertebral body. d Sagittal T1-weighted magnetic resonance imaging shows a pleural mass with high signal intensity in the right paravertebral area at the level of T3 to T6

Contrast-enhanced computed tomography and magnetic resonance imaging study at admission. a Contrast-enhanced chest computed tomography shows a large heterogeneous pleural mass involving the right fifth rib and vertebral body. b Contrast-enhanced abdominopelvic computed tomography shows a mass infiltrating the right renal hilum (longest diameter, 44 mm). c Axial T1-weighted magnetic resonance imaging shows a pleural mass with high signal intensity extending to rib, muscle, and vertebral body. d Sagittal T1-weighted magnetic resonance imaging shows a pleural mass with high signal intensity in the right paravertebral area at the level of T3 to T6 Contrast-enhanced abdominopelvic CT showed a mass infiltrating the right renal hilum without vascular occlusion or hydronephrosis (Fig. 1b). Spine CT and enhanced magnetic resonance imaging (MRI) showed a large pleural mass in the right paravertebral area at the level of T3 to T6 (Fig. 1c, d). CT-guided percutaneous needle biopsy of the pleural mass was performed. Histological findings on hematoxylin and eosin (H&E) staining showed proliferation of spindle cells with infiltration of lymphocytes and plasma cells (Fig. 2a). Immunohistochemistry showed neoplastic cells positive for CD68, focally positive for smooth muscle actin (SMA), and negative for cytokeratin and desmin (Fig. 2b). IMT was diagnosed based on the histological examination.
Fig. 2

a Histological examination (hematoxylin-eosin staining) shows spindle cell proliferation with infiltration of lymphocytes and plasma cells. b Immunohistochemically, neoplastic cells are focally positive for smooth muscle actin

a Histological examination (hematoxylin-eosin staining) shows spindle cell proliferation with infiltration of lymphocytes and plasma cells. b Immunohistochemically, neoplastic cells are focally positive for smooth muscle actin As the tumor could not be completely resected, treatment with glucocorticoids (methylprednisolone 1 mg/kg) and radiotherapy (5 days/week for 3 weeks at 3 Gy/fraction, 45 Gy/15 days) was started. After 1 month, laboratory findings were unremarkable. Hematuria, which is thought to be caused by kidney metastasis of IMT improved after treatment (Table 1). Chest CT showed reduction in the size of the pleural mass (6.0 cm × 1.8 cm × 5.3 cm) and abdominopelvic CT showed decreased infiltration around the right renal pelvis (Fig. 3). The summed-up diameters of both target lesions decreased from 121 mm to 91 mm, that is, a 24.8% reduction of baseline diameter. According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria it could be defined as stable disease. He was discharged on orally administered glucocorticoids and showed improvement in symptoms on follow-up 1 month after hospital discharge. Since then, however, he has not attended a follow-up visit.
Fig. 3

Contrast-enhanced computed tomography after 1 month of treatment. a Contrast-enhanced chest computed tomography shows reduction in size of the pleural mass. b Contrast-enhanced abdominopelvic computed tomography shows decreased infiltration around the right renal pelvis (longest diameter, 31 mm)

Contrast-enhanced computed tomography after 1 month of treatment. a Contrast-enhanced chest computed tomography shows reduction in size of the pleural mass. b Contrast-enhanced abdominopelvic computed tomography shows decreased infiltration around the right renal pelvis (longest diameter, 31 mm)

Discussion

IMT is a mesenchymal neoplasm composed of myofibroblastic and fibroblastic spindle cells accompanied with an inflammatory infiltrate of plasma cells, lymphocytes, and/or eosinophils; it mainly affects children and young adults. IMT has also been known as fibrous histiocytoma, inflammatory pseudotumor, xanthogranuloma, fibroxanthoma, plasma cell granuloma, and inflammatory fibrosarcoma [3]. IMT most commonly occurs in the lung, but can also appear in the mesentery, omentum, retroperitoneum, pelvis, abdominal soft tissue, mediastinum, head and neck, upper respiratory tract, trunk, and extremities [1]. However, pleural involvement is rare and has only been described in a few case reports [6-8]. In our case, pleural IMT invaded the adjacent chest wall; vertebral body invasion and metastasis to the kidney were also present. The etiology and pathogenesis are unknown. Several theories have suggested involvement of the immunologic response to infectious agents such as Epstein–Barr virus or human herpesvirus 8, or an inflammatory reaction to an underlying low-grade malignancy [9]. Griffin et al. reported three cases of IMT with chromosomal rearrangements involving the anaplastic lymphoma kinase (ALK) locus at 2p23 [10]. These findings suggest that IMT is a neoplastic rather than reactive subset [10]. ALK-positive IMTs may be associated with local recurrence and favorable prognosis, but not metastasis [11]. In our case, the patient presented upper back pain and motor weakness in both lower extremities due to IMT involving pleura and vertebra body. Laboratory findings showed an elevated erythrocyte sedimentation rate and elevated C-reactive protein. In addition, urine analysis showed hematuria at admission due to metastasis to the kidney. The clinical features are determined using the location of IMT, with 15% to 30% of patients presenting with fever, weight loss, and malaise. Laboratory findings include an elevated erythrocyte sedimentation rate, elevated C-reactive protein, microcytic hypochromic anemia, and thrombocytosis [12]. Signs and symptoms of kidney IMT may include flank pain, hydronephrosis, and hematuria [13]. Imaging findings vary according to the site of involvement. Pulmonary IMTs usually present with a solitary, peripheral, circumscribed, lobulated mass on chest radiography. Chest CT shows heterogeneous attenuation and enhancement. An amorphous, mixed, or fine fleck-like pattern of calcification has been reported in pulmonary IMTs. MRI shows homogeneous or heterogeneous signal intensity on T1-weighted and T2-weighted images. Kidney IMTs show homogeneous or cystic masses on enhanced CT [13-15]. Enhanced CT of pleural IMT has been described as showing hypodense or heterogeneous masses [6-8]. Our case showed a heterogeneous pleural mass in the contrast-enhanced chest CT and a pleural mass with high signal intensity in T1-weighted MRI. Fluorodeoxyglucose-positron emission tomography (FDG-PET)/CT of IMT showed variable FDG uptake according to tumor cellularity, tumor cell biological behavior, and the extent of activation of inflammatory cells [16]. The most accurate diagnostic method is surgical excision of the lesion. Fine-needle aspiration is often unable to diagnose the disease because specimens are aseptic and show a mixture of inflammatory cells [5]. The diagnosis of IMT requires identification of characteristic pathological features. The histological features of IMT include variable spindle cell proliferation in a myxoid-to-collagenous stroma with a prominent inflammatory infiltrate composed primarily of plasma cells and lymphocytes, with occasional admixed eosinophils and neutrophils. Immunohistochemical investigation is not required to confirm the diagnosis because of the variable expression and lack of specificity of myofibroblastic markers [2]. The treatment of choice for IMT is complete surgical resection. In this case report, our patient was unable to undergo complete surgical resection because IMT invaded the adjacent chest wall. So, if patients have contraindications to surgical resection, or have unresectable or locally aggressive disease, glucocorticoids, chemotherapy, and radiotherapy can be used. Steroid therapy has shown good response in many studies. Various cytotoxic drugs or regimens (vincristine, cyclophosphamide, doxorubicin, 5-fluorouracil, cisplatin, carboplatin, paclitaxel, methotrexate, vinorelbine, ifosfamide, and etoposide) have been used for treatment with unresectable and/or relapsed IMT in a case series. Recently, Maruyama et al. suggested that vinorelbine and methotrexate is a therapeutic option for adult patients with relapsed and unresectable IMT [17]. Radiotherapy may be considered for patients with postoperative recurrences and unresectable IMT [18]. However, there was a lack of clinical evidence and efficacy; also, failures of these modalities have been reported [5, 19, 20]. Although we could not do a long-term follow-up, our case observed a decrease in the size of the mass with radiotherapy and corticosteroid therapy. Butrynski et al. reported a sustained partial response to the ALK inhibitor crizotinib in a patient with ALK-translocated IMT [21]. The recurrence rate varies according to the site of involvement, from < 2% for tumors confined to the lung to 25% for extrapulmonary IMTs associated with an abdominopelvic site, multinodular tumor masses, and incomplete resection. Distant metastasis is rare [2, 3]. Development of metastasis may be more frequent in the absence of ALK reactivity [11].

Conclusions

We presented a rare case of pleural IMT involving the adjacent chest wall and kidney metastasis. IMT is a rare neoplasm of intermediate malignant potential, with a tendency toward local recurrence and rare distant metastasis. Complete surgical resection of IMT is the primary treatment. However, unresectable and metastatic IMT can be treated with systemic therapy, including glucocorticoids, radiotherapy, and/or chemotherapy.
  20 in total

Review 1.  Inflammatory pseudotumor.

Authors:  Lakshmana Das Narla; Beverley Newman; Stephanie S Spottswood; Shireesha Narla; Rajasekhar Kolli
Journal:  Radiographics       Date:  2003 May-Jun       Impact factor: 5.333

2.  Bilateral multiple inflammatory myofibroblastic tumors of the lung successfully treated with corticosteroids.

Authors:  Min Hee Lee; Heung Bum Lee; Yong Chul Lee; Yang Keun Rhee; Eun Jung Lee; Myoung Ja Chung; Gong Yong Jin; Eui Yong Kweon; Seoung Ju Park
Journal:  Lung       Date:  2011-08-02       Impact factor: 2.584

3.  Pulmonary inflammatory pseudotumor: radiologic features.

Authors:  G A Agrons; M L Rosado-de-Christenson; W M Kirejczyk; R M Conran; J T Stocker
Journal:  Radiology       Date:  1998-02       Impact factor: 11.105

Review 4.  Extrapulmonary inflammatory myofibroblastic tumor: a clinical and pathological survey.

Authors:  C M Coffin; P A Humphrey; L P Dehner
Journal:  Semin Diagn Pathol       Date:  1998-05       Impact factor: 3.464

5.  Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors.

Authors:  C A Griffin; A L Hawkins; C Dvorak; C Henkle; T Ellingham; E J Perlman
Journal:  Cancer Res       Date:  1999-06-15       Impact factor: 12.701

6.  Recurrent inflammatory myofibroblastic tumor of the inguinal region: A case report and review of the literature.

Authors:  Tian Zhang; Yawei Yuan; Chen Ren; Shasha DU; Jiarong Chen; Quanquan Sun; Zhengjun Liu
Journal:  Oncol Lett       Date:  2015-05-29       Impact factor: 2.967

7.  Inflammatory myofibroblastic tumor: FDG PET/CT findings with pathologic correlation.

Authors:  Aisheng Dong; Yang Wang; Hui Dong; Jing Gong; Chao Cheng; Changjing Zuo; Jianping Lu
Journal:  Clin Nucl Med       Date:  2014-02       Impact factor: 7.794

8.  Inflammatory pseudotumor of the lung in adults.

Authors:  Giulio Melloni; Angelo Carretta; Paola Ciriaco; Gianluigi Arrigoni; Stefano Fieschi; Nathalie Rizzo; Edgardo Bonacina; Giuseppe Augello; Pier Angelo Belloni; Piero Zannini
Journal:  Ann Thorac Surg       Date:  2005-02       Impact factor: 4.330

9.  Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases.

Authors:  Cheryl M Coffin; Jason L Hornick; Christopher D M Fletcher
Journal:  Am J Surg Pathol       Date:  2007-04       Impact factor: 6.394

Review 10.  Inflammatory myofibroblastic tumours: where are we now?

Authors:  B C Gleason; J L Hornick
Journal:  J Clin Pathol       Date:  2007-10-15       Impact factor: 3.411

View more
  9 in total

1.  Clinical and pathological characteristics of patients with pulmonary inflammatory pseudotumors: An 18-year retrospective study of 31 cases.

Authors:  Heng-Chi Chen; Qiang Fu; Yan Song; Da-Li Wang
Journal:  Medicine (Baltimore)       Date:  2021-09-03       Impact factor: 1.817

2.  A Rare Case of Inflammatory Myofibroblastic Tumor Causing Left Pulmonary Artery Stenosis and Successfully Treated with Localized Radiotherapy in a Patient with Perinuclear Antineutrophil Cytoplasmic Antibody Vasculitis.

Authors:  Claire P Browne; Cady Zeman-Pocrnich; A Rashid Dar; Blair Wyllie; Mariamma Joseph
Journal:  Cureus       Date:  2020-01-20

3.  Kidney inflammatory myofibroblastic tumor masquerading as metastatic malignancy: A case report and literature review.

Authors:  Guo-Hui Zhang; Xiao-Yan Guo; Gao-Zhao Liang; Qing Wang
Journal:  World J Clin Cases       Date:  2019-12-26       Impact factor: 1.337

4.  Mini-invasive endoscopic approach to tracheal inflammatory myofibroblastic tumor in a young woman: A case report.

Authors:  Sara Zarrouki; Rachid Marouf
Journal:  Ann Med Surg (Lond)       Date:  2021-12-22

5.  Genetic Testing and Immunotherapy for Intracranial Inflammatory Myofibroblastic Tumor: A Case Report.

Authors:  Xiangji Meng; Lei Zhang; Qi Wang; Jimin Chen; Chunmei Zhang; Rongjie Tao; Yong Wang
Journal:  Onco Targets Ther       Date:  2022-04-01       Impact factor: 4.147

6.  Common Presentation of Uncommon Disease: Inflammatory myofibroblastic tumor of the lung, case report.

Authors:  Safwat Eldaabossi; Lotfi Maghmoul; Elsaid Lotfy; Ahmad Antar; Yasser Elghoneimy; Hameed Aljawad; Ayman Ghoneim
Journal:  Respir Med Case Rep       Date:  2022-04-26

7.  Extra-skeletal Ewing Sarcoma of the chest wall in a child.

Authors:  Denny Mathew; Daniel N Prince; Nasreen Mahomed
Journal:  SA J Radiol       Date:  2019-06-27

8.  A fatal multiple-lesion, inflammatory, pseudotumor in the lung: a rare case report.

Authors:  Na Li; Changpeng Zou; Siming Gao; Ying Guo; Wei Wang; Yan Guo; Juan Zhang; Cong Wang; Yonghui An
Journal:  Transl Cancer Res       Date:  2021-04       Impact factor: 1.241

9.  Microwave ablation for the management of pulmonary inflammatory myofibroblastic tumor: a case report and literature review.

Authors:  Yizhong Zhang; Guoping Zheng; Xiaopeng Meng; Yuanjing Li; Dan Shi; Jinna Yu
Journal:  Transl Cancer Res       Date:  2021-10       Impact factor: 1.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.